Matuzumab: Difference between revisions
m Protected "Matuzumab": Protecting pages from unwanted edits ([edit=sysop] (indefinite) [move=sysop] (indefinite)) |
m Robot: Automated text replacement (-{{SIB}} + & -{{EH}} + & -{{EJ}} + & -{{Editor Help}} + & -{{Editor Join}} +) |
||
| Line 26: | Line 26: | ||
}} | }} | ||
{{SI}} | {{SI}} | ||
==Overview== | ==Overview== | ||
| Line 40: | Line 40: | ||
{{humanizedmonoclonals}} | {{humanizedmonoclonals}} | ||
[[Category:Monoclonal antibodies]] | [[Category:Monoclonal antibodies]] | ||
[[Category:Cancer treatments]] | [[Category:Cancer treatments]] | ||
Latest revision as of 17:13, 9 August 2012
|
WikiDoc Resources for Matuzumab |
|
Articles |
|---|
|
Most recent articles on Matuzumab |
|
Media |
|
Evidence Based Medicine |
|
Clinical Trials |
|
Ongoing Trials on Matuzumab at Clinical Trials.gov Clinical Trials on Matuzumab at Google
|
|
Guidelines / Policies / Govt |
|
US National Guidelines Clearinghouse on Matuzumab
|
|
Books |
|
News |
|
Commentary |
|
Definitions |
|
Patient Resources / Community |
|
Patient resources on Matuzumab Discussion groups on Matuzumab Directions to Hospitals Treating Matuzumab Risk calculators and risk factors for Matuzumab
|
|
Healthcare Provider Resources |
|
Causes & Risk Factors for Matuzumab |
|
Continuing Medical Education (CME) |
|
International |
|
|
|
Business |
|
Experimental / Informatics |
Overview
Matuzumab (formerly EMD 72000) is a humanized monoclonal antibody for the treatment of cancer. It binds to EGFR (epithelial growth factor receptor) with high affinity.
Developed by Merck Serono in cooperation with Takeda Pharmaceutical, it is currently undergoing phase II clinical trials for the treatment of colorectal, lung and stomach cancer. On August 29, 2007, Merck Serono announced that the preliminary results of the colorectal cancer study were less than promising, and that further trials for treating this type of cancer may be abandoned. The results of the lung and stomach cancer studies are expected in 2008.[1]
Footnotes
- ↑ Krebsmedikament floppt. n-tv, August 29, 2007. [Article in Gemran]. Retrieved 2007-AUG-27.